RC
YARW

Rangeley Capital’s Yarrow Bioscience YARW Stock Holding History

Rangeley Capital’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.6K Sell
2,261
-100
-4% -$3.24K 0.07% 156
2026
Q1 		$70.5K Buy
2,361
+361
+18% +$10.5K 0.07% 126
2025
Q4 		$58K Buy
2,000
+1,000
+100% +$20.1K 0.05% 113
2025
Q3 		$16.8K Buy
+1,000
New +$32.7K 0.01% 127

Other funds holding YARW

ADAR1 Capital Management
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Shay Capital
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Deeter Investments
Deeter Investments Austin, Texas $721M AUM
TC
T3 Companies New York $93.7M AUM
Braidwell
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rangeley Capital's YARW Position: Q2 2026 in Review

Rangeley Capital reduced its Yarrow Bioscience (YARW) stake by 4.2% in Q2 2026, selling an estimated $3.24K and leaving 2,261 shares worth $73.6K. The position accounts for 0.07% of the portfolio, ranked #156.

Rangeley Capital first reported a position in YARW in Q3 2025 and has held it in 4 quarters since. 41 funds tracked by Wall St. Rank hold YARW as of Q2 2026.

  • Rangeley Capital held 2,261 shares of Yarrow Bioscience worth $73.6K as of Q2 2026.
  • Rangeley Capital sold 100 Yarrow Bioscience shares in Q2 2026, an estimated $3.24K.
  • Yarrow Bioscience made up 0.07% of Rangeley Capital's portfolio in Q2 2026, its #156 holding.
  • Rangeley Capital first reported a position in Yarrow Bioscience in Q3 2025 and has held it in 4 quarters since.
  • 41 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.